M. Skiadopoulos

发表

CFTR Delivery to 25% of Surface Epithelial Cells Restores Normal Rates of Mucus Transport to Human Cystic Fibrosis Airway Epithelium

Leatrice N Vogel, P. Collins, R. Boucher, 2009, PLoS biology.

Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation Anthrax

M. Al-Ibrahim, S. Basu, R. Hopkins, 2013, Antimicrobial Agents and Chemotherapy.

Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis

T. Rudge, T. Guina, A. Innes, 2013, Clinical and Vaccine Immunology.

Replacement of the Ectodomains of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins of Recombinant Parainfluenza Virus Type 3 (PIV3) with Their Counterparts from PIV2 Yields Attenuated PIV2 Vaccine Candidates

B. Murphy, P. Collins, F. Davoodi, 2000, Journal of Virology.

A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.

B. Murphy, P. Collins, A. Durbin, 2000, Vaccine.

Bovine Parainfluenza Virus Type 3 (BPIV3) Fusion and Hemagglutinin-Neuraminidase Glycoproteins Make an Important Contribution to the Restricted Replication of BPIV3 in Primates

J. McAuliffe, P. Collins, A. Schmidt, 2000, Journal of Virology.

The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically, and the Fusion (F) Protein Is a Major Contributor to This Antigenic Relatedness

M. St. Claire, B. Murphy, J. McAuliffe, 2004, Journal of Virology.

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.

B. Murphy, P. Collins, S. Biacchesi, 2004, Virology.

Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.

M. St. Claire, B. Murphy, P. Collins, 2002, Virology.

Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.

B. Murphy, K. Zoon, P. Collins, 2006, Virology.

More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved?

B. Murphy, J. McAuliffe, P. Collins, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Sequence Analysis of the Washington/1964 Strain of Human Parainfluenza Virus Type 1 (HPIV1) and Recovery and Characterization of Wild-Type Recombinant HPIV1 Produced by Reverse Genetics

B. Murphy, P. Collins, J. Newman, 2004, Virus Genes.

Mutational analysis of conserved tyrosines in the NS-1 protein of the parvovirus minute virus of mice.

E. A. Faust, M. Skiadopoulos, 1993, Virology.

The bovine papillomavirus type 1 E2 transactivator and repressor proteins use different nuclear localization signals

A. McBride, M. Skiadopoulos, Andalison A. Mcbride, 1996, Journal of virology.

Two spatially distinct genetic elements constitute a bipartite DNA replication origin in the minute virus of mice genome

C. Astell, R. Salvino, E. A. Faust, 1991, Journal of virology.

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.

B. Murphy, P. Collins, C. Orvell, 2002, Virology.

A Chimeric Human-Bovine Parainfluenza Virus Type 3 Expressing Measles Virus Hemagglutinin Is Attenuated for Replication but Is Still Immunogenic in Rhesus Monkeys

B. Murphy, P. Collins, S. Surman, 2001, Journal of Virology.

Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization against Measles Virus and PIV3 in Early Infancy

B. Murphy, J. McAuliffe, P. Collins, 2000, Journal of Virology.

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.

B. Murphy, P. Collins, Emérito Amaro-Carambot, 2006, Vaccine.

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

B. Murphy, P. Collins, Emérito Amaro-Carambot, 2005, Vaccine.

Codon Substitution Mutations at Two Positions in the L Polymerase Protein of Human Parainfluenza Virus Type 1 Yield Viruses with a Spectrum of Attenuation In Vivo and Increased Phenotypic Stability In Vitro

B. Murphy, J. McAuliffe, P. Collins, 2004, Journal of Virology.

Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.

V. Savransky, B. Ionin, Sukjoon Park, 2020, Vaccine.

Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans

E. Bernton, E. Vela, R. Aimes, 2014, Antimicrobial Agents and Chemotherapy.

Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White Rabbits

T. Rudge, R. Aimes, S. Basu, 2013, Antimicrobial Agents and Chemotherapy.

BIOTHRAX ® (ANTHRAX VACCINE ADSORBED) FOR POST-

T. Rudge, T. Guina, A. Innes, 2013 .

Use of deletion and point mutants spanning the coding region of the adenovirus 5 E1A gene to define a domain that is essential for transcriptional activation.

J. Howe, S. Bayley, C. Evelegh, 1988, Virology.

Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression.

B. Murphy, P. Collins, S. Biacchesi, 2005, Journal of virological methods.

Infection of Nonhuman Primates with Recombinant Human Metapneumovirus Lacking the SH, G, or M2-2 Protein Categorizes Each as a Nonessential Accessory Protein and Identifies Vaccine Candidates

B. Murphy, P. Collins, S. Biacchesi, 2005, Journal of Virology.

Efficacy of atropine sulfate/obidoxime chloride co-formulation against sarin exposure in guinea pigs.

E. Verheij, M. Skiadopoulos, M. Joosen, 2018, Chemico-biological interactions.

Modification of the Trypsin-Dependent Cleavage Activation Site of the Human Metapneumovirus Fusion Protein To Be Trypsin Independent Does Not Increase Replication or Spread in Rodents or Nonhuman Primates

B. Murphy, P. Collins, S. Biacchesi, 2006, Journal of Virology.

Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.

B. Murphy, P. Collins, S. Biacchesi, 2006, Virology.

Chimeric Recombinant Human Metapneumoviruses with the Nucleoprotein or Phosphoprotein Open Reading Frame Replaced by That of Avian Metapneumovirus Exhibit Improved Growth In Vitro and Attenuation In Vivo

B. Murphy, P. Collins, S. Biacchesi, 2005, Journal of Virology.

Deletion of M2 Gene Open Reading Frames 1 and 2 of Human Metapneumovirus: Effects on RNA Synthesis, Attenuation, and Immunogenicity

B. Murphy, P. Collins, S. Biacchesi, 2005, Journal of Virology.

Recombinant Human Metapneumovirus Lacking the Small Hydrophobic SH and/or Attachment G Glycoprotein: Deletion of G Yields a Promising Vaccine Candidate

B. Murphy, P. Collins, S. Biacchesi, 2004, Journal of Virology.

Associated with Mitotic Chromatin the E 2 Transactivator Protein Are Closely Bovine Papillomavirus Type 1 Genomes and

A. McBride, M. Skiadopoulos, 1998 .

Bridging Animal and Human Data in Pursuit of Vaccine Licensure

N. Sullivan, W. Dowling, R. Roozendaal, 2022, Vaccines.

Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

B. Murphy, P. Collins, Konrad C. Bradley, 2010, Virology.

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

B. Murphy, P. Collins, A. Schmidt, 2010, Vaccine.

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

M. St. Claire, B. Murphy, P. Collins, 2007, Vaccine.

Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes

B. Murphy, P. Collins, S. Surman, 2007, Virology Journal.

L-histidinol dehydrogenase, a Zn2+-metalloenzyme.

C. Grubmeyer, A. E. Senior, M. Skiadopoulos, 1989, Archives of biochemistry and biophysics.

Bovine Papillomavirus Type 1 Genomes and the E2 Transactivator Protein Are Closely Associated with Mitotic Chromatin

A. McBride, M. Skiadopoulos, 1998, Journal of Virology.

Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza3 viruses.

B. Murphy, S. Moyer, S. Smallwood, 2000, Virology.

Three Amino Acid Substitutions in the L Protein of the Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine Candidate Contribute to Its Temperature-Sensitive and Attenuation Phenotypes

B. Murphy, P. Collins, J. Tatem, 1998, Journal of Virology.

Generation of Recombinant Human Parainfluenza Virus Type 1 Vaccine Candidates by Importation of Temperature-Sensitive and Attenuating Mutations from Heterologous Paramyxoviruses

B. Murphy, J. McAuliffe, P. Collins, 2004, Journal of Virology.

Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine

P. Collins, S. Udem, J. Tatem, 1999, Journal of Virology.

A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.

B. Murphy, P. Collins, A. Durbin, 1999, Vaccine.

Mutational analysis of the NS-1 protein of the MVM parvovirus.

M. Skiadopoulos, 1993 .

Characterization of linker insertion and point mutations in the NS-1 gene of minute virus of mice: effects on DNA replication and transcriptional activation functions of NS-1.

W. Leong, R. Salvino, E. A. Faust, 1992, Virology.

Nonsegmented Negative-Strand Viruses as Vaccine Vectors

B. Murphy, P. Collins, A. Bukreyev, 2006, Journal of Virology.

An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.

B. Murphy, P. Collins, S. Surman, 2007, Journal of virological methods.

The Genome Length of Human Parainfluenza Virus Type 2 Follows the Rule of Six, and Recombinant Viruses Recovered from Non-Polyhexameric-Length Antigenomic cDNAs Contain a Biased Distribution of Correcting Mutations

Brian R. Murphy, Peter L. Collins, B. Murphy, 2003, Journal of Virology.

MINIREVIEW Nonsegmented Negative-Strand Viruses as Vaccine Vectors

B. Murphy, P. Collins, A. Bukreyev, 2006 .

Vaccine Licensure in the Absence of Human Efficacy Data

R. Rustomjee, E. Leffel, Courtney L. Finch, 2022, Vaccines.

Sequence Determination and Molecular Analysis of Two Strains of Bovine Parainfluenza Virus Type 3 that are Attenuated for Primates

B. Murphy, J. McAuliffe, P. Collins, 2004, Virus Genes.

Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.

M. St. Claire, B. Murphy, P. Collins, 1999, Virology.

Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses

H. Andersen, N. Grubaugh, T. Guina, 2021, Viruses.

Genetic diversity between human metapneumovirus subgroups.

Guy Boivin, B. Murphy, P. Collins, 2003, Virology.

Determinants of the Host Range Restriction of Replication of Bovine Parainfluenza Virus Type 3 in Rhesus Monkeys Are Polygenic

M. St. Claire, B. Murphy, P. Collins, 2003, Journal of Virology.

Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule

J. Longstreth, R. Hopkins, M. Skiadopoulos, 2016, Expert review of vaccines.

Pathology and Pathophysiology of Inhalational Anthrax in a Guinea Pig Model

K. Tordoff, J. L. Austin, V. Savransky, 2013, Infection and Immunity.

Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

V. Savransky, B. Ionin, G. Stark, 2017, Vaccine.

Repeat-Dose Toxicity Study of a Lyophilized Recombinant Protective Antigen-Based Anthrax Vaccine Adjuvanted With CpG 7909

V. Savransky, B. Ionin, M. Lacy, 2019, International journal of toxicology.

Role of Interferon in the Replication of Human Parainfluenza Virus Type 1 Wild Type and Mutant Viruses in Human Ciliated Airway Epithelium

Brian R. Murphy, Peter L. Collins, B. Murphy, 2008, Journal of Virology.

Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.

B. Murphy, P. Collins, Emérito Amaro-Carambot, 2005, Vaccine.

Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.

B. Murphy, P. Collins, A. Durbin, 2000, Virology.

Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.

B. Murphy, P. Collins, F. Davoodi, 2001, Vaccine.

NINDS launches network to develop treatments for ultra-rare neurological diseases

N. T. Dhruv, C. Lungu, A. Gubitz, 2021, Nature Biotechnology.